HUE052107T2 - Gyógyszerészeti vegyületek - Google Patents

Gyógyszerészeti vegyületek

Info

Publication number
HUE052107T2
HUE052107T2 HUE17790814A HUE17790814A HUE052107T2 HU E052107 T2 HUE052107 T2 HU E052107T2 HU E17790814 A HUE17790814 A HU E17790814A HU E17790814 A HUE17790814 A HU E17790814A HU E052107 T2 HUE052107 T2 HU E052107T2
Authority
HU
Hungary
Prior art keywords
pharmaceutical compounds
pharmaceutical
compounds
Prior art date
Application number
HUE17790814A
Other languages
English (en)
Hungarian (hu)
Inventor
Neil Anthony Pegg
David Michel Adrien Taddei
Jonathan Shannon
Silvia Paoletta
Ting Qin
Gareth Harbottle
Original Assignee
Cellcentric Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellcentric Ltd filed Critical Cellcentric Ltd
Publication of HUE052107T2 publication Critical patent/HUE052107T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
HUE17790814A 2016-10-18 2017-10-18 Gyógyszerészeti vegyületek HUE052107T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1617627.3A GB201617627D0 (en) 2016-10-18 2016-10-18 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
HUE052107T2 true HUE052107T2 (hu) 2021-04-28

Family

ID=57680679

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17790814A HUE052107T2 (hu) 2016-10-18 2017-10-18 Gyógyszerészeti vegyületek

Country Status (12)

Country Link
US (1) US10647704B2 (enExample)
EP (1) EP3529240B1 (enExample)
JP (1) JP7082616B2 (enExample)
CN (1) CN110036002B (enExample)
AU (1) AU2017346454B2 (enExample)
CA (1) CA3039643A1 (enExample)
DK (1) DK3529240T3 (enExample)
ES (1) ES2824814T3 (enExample)
GB (1) GB201617627D0 (enExample)
HU (1) HUE052107T2 (enExample)
WO (1) WO2018073587A1 (enExample)
ZA (1) ZA201902335B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201617630D0 (en) * 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
TWI846350B (zh) 2017-09-15 2024-06-21 美商佛瑪治療公司 作為CBP/p300抑制劑之四氫-咪唑並喹啉化合物
MX2023013508A (es) 2018-06-29 2023-12-13 Forma Therapeutics Inc Inhibicion de la proteina de union a creb (cbp).
TW202102494A (zh) 2019-03-15 2021-01-16 美商弗瑪治療公司 抑制環amp-反應元件-結合蛋白(creb)
CN112574189B (zh) * 2019-09-27 2024-05-31 海创药业股份有限公司 一种ep300/cbp抑制剂
CN112574191B (zh) * 2019-09-29 2024-01-23 南京圣和药业股份有限公司 异噁唑杂环类化合物及其应用
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
TW202227429A (zh) * 2020-11-06 2022-07-16 大陸商貝達藥業股份有限公司 P300抑制劑、包含其的藥物組合物、其應用及製備其的方法
CN116670129A (zh) * 2020-12-31 2023-08-29 南京明德新药研发有限公司 苯并咪唑类化合物及其应用
CN114989158A (zh) * 2021-03-02 2022-09-02 复旦大学 组蛋白乙酰转移酶p300溴结构域抑制剂及其药用组合物及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200501960A (en) * 2002-10-02 2005-01-16 Bristol Myers Squibb Co Synergistic kits and compositions for treating cancer
JP5536336B2 (ja) * 2005-11-08 2014-07-02 チョンウェ ファーマ コーポレイション α−ヘリックス類似体および癌幹細胞の治療に関する方法
US8501957B2 (en) 2008-12-10 2013-08-06 China Medical University Benzimidazole compounds and their use as anticancer agents
WO2011085039A2 (en) * 2010-01-05 2011-07-14 The Johns Hopkins University Use of histone acetyltransferase inhibitors as novel anti-cancer therapies
EP2397471A1 (en) 2010-06-16 2011-12-21 China Medical University Benzimidazole compounds and their use
TWI527811B (zh) 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
WO2015004534A2 (en) * 2013-06-21 2015-01-15 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
US9763922B2 (en) * 2014-11-27 2017-09-19 Genentech, Inc. Therapeutic compounds and uses thereof
WO2016097870A1 (en) 2014-12-17 2016-06-23 Zenith Epigenetics Corp. Substituted bicyclic compounds as bromodomain inhibitors
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
CN114605387A (zh) 2015-08-12 2022-06-10 埃皮吉纳提克斯股份有限公司 取代的苯并咪唑、它们的制备和它们作为药物的用途
GB201617630D0 (en) * 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
CA3039643A1 (en) 2018-04-26
US10647704B2 (en) 2020-05-12
ES2824814T3 (es) 2021-05-13
ZA201902335B (en) 2024-11-27
DK3529240T3 (da) 2020-09-07
JP2019535658A (ja) 2019-12-12
WO2018073587A1 (en) 2018-04-26
EP3529240B1 (en) 2020-08-05
US20190263788A1 (en) 2019-08-29
CN110036002B (zh) 2022-08-30
AU2017346454B2 (en) 2022-02-17
GB201617627D0 (en) 2016-11-30
JP7082616B2 (ja) 2022-06-08
AU2017346454A1 (en) 2019-05-02
NZ752356A (en) 2025-02-28
EP3529240A1 (en) 2019-08-28
CN110036002A (zh) 2019-07-19

Similar Documents

Publication Publication Date Title
SI3529248T1 (sl) Farmacevtske spojine
EP3513809A4 (en) MEDICAL COMPOSITION
DK3474804T4 (da) Medicinsk forbinding
IL262335A (en) Stable nimopidine parenteral formulation
PT3298027T (pt) Compostos depsipéptidos antelmínticos
SI4070787T1 (sl) Farmacevtske formulacije
DK3529240T3 (da) Farmaceutiske forbindelser
EP3424940A4 (en) Radiolabeled drug
DK3463345T3 (da) Farmaceutiske kombinationer
DK3199161T3 (da) Farmaceutisk præparat
SMT202200173T1 (it) Composti
EP3603642A4 (en) PHARMACEUTICAL PREPARATION
DK3145488T3 (da) Flydende farmaceutiske forbindelse
EP3437644A4 (en) MEDICINE
HUE054351T2 (hu) Vegyületek
DK3597189T3 (da) Krystallinske forbindelser
DK3256154T3 (da) Farmaceutisk formulering omfattende antistof
BR112018001062A2 (pt) compostos inovadores
DK3280447T3 (da) Farmaceutiske formuleringer
EP3646866A4 (en) PHARMACEUTICAL PREPARATION
EP3527216A4 (en) Medicine
DK3728220T3 (da) Farmaceutiske forbindelser
DK3672941T3 (da) Pyridylpyridonforbindelser
HUE069648T2 (hu) Gyógyszerészeti készítmény
LT3331885T (lt) Junginiai